Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported R&D Expense of $4.17 million for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.17M | -10.2% |
| 2024 | $4.65M | -56.7% |
| 2023 | $10.75M | -23.0% |
| 2022 | $13.96M | -8.4% |
| 2021 | $15.23M | -31.8% |
| 2020 | $22.33M | +29.8% |
| 2019 | $17.20M | +107.5% |
| 2018 | $8.29M | +748.8% |
| 2017 | $977.0K | -56.6% |
| 2016 | $2.25M | -54.5% |
| 2015 | $4.95M | +3.7% |
| 2014 | $4.77M | +63.6% |
| 2013 | $2.92M | +64.8% |
| 2012 | $1.77M | +4.8% |
| 2011 | $1.69M | +61.6% |
| 2010 | $1.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $899.0K | -14.0% | -19.7% |
| June 30, 2025 | $1.12M | +21.5% | -14.1% |
| March 31, 2025 | $1.30M | +35.7% | +24.8% |
| September 30, 2024 | $1.04M | -68.6% | +13.3% |
| June 30, 2024 | $922.0K | -67.0% | -4.1% |
| March 31, 2024 | $961.0K | -67.1% | -71.1% |
| September 30, 2023 | $3.33M | -11.8% | +19.2% |
| June 30, 2023 | $2.79M | -45.4% | -4.4% |
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -10.2% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, BRAINSTORM CELL THERAPEUTICS INC.’s r&d expense has grown by 299.5% (from $1.04 million to $4.17 million).
- The most recent figure is from BRAINSTORM CELL THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: